Australian biotechnology company PharmAust (ASX:PAA) has announced that the first patient has been dosed in its Phase 1/2 clinical trial testing the effects of its monepantel in people living with motor neurone disease. …
Australian company doses first patient in MND clinical trial
October 3, 2022 Latest NewsAustralian Biotech
Latest Video
New Stories
-
The regulator that deleted the truth from its answers now wants to police the media
October 1, 2026 - - Latest News -
By the TGA's own test, the Health Minister's press releases are advertising
October 1, 2026 - - Latest News -
Eczema patients who don't respond to steroids get subsidised access to ointment
October 1, 2026 - - Latest News -
Vitrafy takes its frozen platelet push to America's Midwest
September 30, 2026 - - Australian Biotech -
Paradigm Biopharmaceuticals enters voluntary administration after Phase 3 setback
September 30, 2026 - - Australian Biotech -
FDA fast tracks Telix scan that could spare men prostate biopsies
September 30, 2026 - - Australian Biotech -
Australian broadcast personality reveals the scars shingles left behind
September 30, 2026 - - Latest News